BioSpace

FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Fierce Pharma

FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype

Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

Pfizer, Arvinas win FDA nod for first-of-its-kind breast cancer therapy

Pfizer Inc. PFE and partner Arvinas Inc. ARVN shares rose Monday after the companies secured a key regulatory win, with the U ...

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...